The aim of this study was to produce fl uconazole loaded liposomal nanoparticles, to analyze their physicochemical properties and to compare their antifungal effects with the free fl uconazole drug in vitro against the fl uconazole susceptible and resistant Candida species isolated from patients. Six common candida species including C.albicans, C.parapsilosis, C.tropicalis, C.glabrata, C.krusei and C.guilliermondii were tested. The Liposomal nanoparticles were prepared using thin layer hydration method and soybean lecithin, cholesterol, and fl uconazole at a ratio of 10: 1: 1. The nanoparticles were analyzedin terms of size, poly dispersity index, zeta potential, morphology, entrapment effi ciency of drug and the amount of drug released. nanoparticles and compare them with the free form of fl uconazole, we used Broth Microdilution as described in CLSI M27-A3.The results were analyzed using Student's T-test and indicated the greater antifungal effects of the liposomal nanoparticles containing fl uconazole than the normal form of the drug. It was shown that MIC of Fluconazole was put in the range of sensitive species after exposure with the Fluconazole Nanoliposomal in most Fluconazole resistant Candida species except for the krusei species. Therefore, it is likely that we can use the new system for drug delivery to prevent drug release from the cell. In addition, this is the fi rst research using fl uconazole lipid nanoparticles against C.krusei.
INTRODUCTION
Nowadays, the opportunistic pathogenic fungi are among the life threatening infections in patients with impaired immune systems. Yeasts, especially the candida species are the most common fungi that are isolated from human infections. Despite many advances in the fi eld of health care and methods of treatment, the incidence of invasive systemic candidiasis is signifi cantly increasing. Although Candida albicans was and is the most common agent responsible for infections in different clinical forms of candidiasis, the other species belong to the Candida types such as Candida tropicalis, Candida glabrata, Candida krusei, Candida parapsilosis, Candida guilliermondii and so on, are more or less isolated from patients. The importance of the non-albicans species has increased due to the relative resistance in some of these species like Candida tropicalis and Candida glabrata to the antifungal drugs in the recent years, (Price etal 1994 , Pfaller, 1995 , Wingard, 1995 Neppelenbroek et al 2006 .
The increase of the different and various reports from all over the world about the drug resistance increase among the fungi and Candida species, and on the other hand, the new antifungal drugs production indicates the need for testing the susceptibility to these drugs and makes the researchers eager to determine susceptibility pattern for the various antifungal drugs, (White et al., 2002 Mohammadi et al 2016 .
The side effects of anti-fungal drugs is one of the main reasons of extensive research on new anti-fungal compounds and their therapeutic effects, (FalkiewiczDulik and Macura, 2008) . Meanwhile nano particles are of the particular importance, among the metal nano particles, silver nano particles has attracted many researchers due to their interesting physicochemical traits (S. Schultz et al., 2000) . Recently nano particles synthesis by microbes has been considered as a suitable alternative for the mass production of nano particles, (Verma et al 2009 and Omidi et al., 2014) . Solid lipid nanoparticles (SLNs) were introduced for the fi rst time in 1991 as an alternative to common colloidal carriers such as emulsions and polymeric nanoparticles. SLNs are colloidal carriers with sizes ranging from 50 to 1000 nm, which are formed from biolipids (Thassu et al., 2007 , Yadav et al., 2013 .
Recently, these particles are used as antifungal drug carriers such as Itraconazole, (Mohanty et al., 2015) , ketoconazole (Souto and Muller, 2005) , Griseofulvin (Aggarwal and Goindi, 2013) and Miconazole ( Mendes et al., 2013) . The small size of these lipid nanoparticles increases their access to the tissues and the more infl uence of drugs ( Jenning et al., 2000) . These drug delivery systems bring the controlled release of drugs, increasing chemical stability of the trapped drugs. In addition, these systems are among the safe and secure carriers that can be easily produced on a large scale (Muhlen et al., 1998 and Mehnert and Mader, 2001) .
The treatment using azole antifungal agents, especially, fl uconazole is introduced as an effective solution for treating infections caused by Candida, but the drug resistances have faced this treatment method with diffi culties ( Revankar et al., 1996 , Silva et al., 2012 .
Thus, for treating these types of cases, that are not curable applying the conventional methods, the use of new treatment strategies seems to be essential. In this research, nanoliposome-containing fl uconazole is prepared, and its antifungal effects are studied in vitro on the fl uconazole susceptible and resistant strains of C.albicans, C.parapsilosis, C.glabrata, C.tropicalis and the resistant C.krusei species comparing to the conventional form of fl uconazole.
MATERIALS AND METHODS
87 positive cultures of yeast organisms isolated from cutaneous, mucosal and systemic fungal lesions of patients referring Razi hospital in Tehran, Sina Hospital in Tabriz city and another private lab in Tabriz were collected. Clinical specimens included skin, nail, mucous discharges and the BAL samples.
Isolation of yeast: clinical samples were cultured on Sabouraud dextrose agar medium with chloramphenicol, and after the growth of yeast colonies were transferred to sterile Eppendorf tubes containing distilled water and 20% glycerol so were kept in the freezer with -20 ° C.CHROMagar Candida culture medium: Yeasts isolated from patients were cultured applying linear method on the CHROMagar Candida medium in HIMEDIA Company and incubated for 48 hours at 35 ° C and then the plates were examined macroscopically. For the green samples testing of Candida albicans/dubliniensis, chlamydocanidia and mycelium forms production using corn meal agar medium containing Tween 80 for 48 hours at 30 ° C was carried out.To differentiate albicans species from dubliniensis the test of chlamydoconidia production by dubliniensis species in Niger seed agar medium and the inability of C.albicans was used in the production of chlamydoconidia in the mentioned medium.
The identifi cation of Non-Albicans candidaisolates: all of the yeasts that their colony color was not exclusive to identify them in CHROMagar medium and isolates that their color was blue and purple in CHROMagar Candida agar medium were identifi ed using PCR-RFLP. This method is based on amplifi cation of ribosomal DNA fragments in ITS1-5.8S-ITS2 PCR method using universal primers ITS1, ITS4 and then digestion the PCR products amplifi ed by restriction enzyme HpaII. (fi gure 1, 2)
PREPARATION OF LIPOSOME
Fluconazole and cholesterol were purchased from Sigma company, and soybean lecithin was purchased from Lipoid Company. Liposomal formulation fl uconazole was prepared by the method of thin layer fi lm hydration (H. Ola et al., 2010) .
For the preparation of liposomes, lecithin, cholesterol and fl uconazole were used with a ratio of 10: 1: 1. A thin layer was formed by solving these two substances in the organic solvent of chloroform-methanol (1: 1) containing fl uconazole at a rate of 5.12mg / ml, then evaporation of the solvent in the rotary evaporator under the temperature of 45 ° C. Then, it was hydrated by 9% sucrose slowly at 65 ° C. The homogenization action of samples was performed by a homogenizer at 20000 rpm and ata temperature above the liposomes phase transition (70) for 10 minutes. The liposomal sample sonication operation was carried out in an ice bath. The amount of the drug that was not loaded, by the amicon fi lter was removed by centrifugation at 4000 × g for 4 minute and was passed for sterilization twice using 0/22 micron fi lter needle. This new formulation transferred to the laboratory and used freshly to evaluate the antifungal activity.
BLANK LIPOSOMAL PREPARATION
To prepare this formulation, it was treatedin accordance with the formulation of fl uconazole liposomal formulations and the difference was that it was prepared without fl uconazole.Determining the size of nanoliposomes containing fl uconazole:Particle size, average diameter, nanoliposome zeta potential distribution was measured by zetasizer device based on laser light scattering. Particle size distribution in the device, was evaluated based on PDI (Poly Dispersity Index).
NANOPARTICLE STRUCTURE
For this purpose, the scanning electron microscope device was used. That a quantity of sample is placed on a glass surface with dimensions of 1 x 1 cm. Then it was placed inside an incubator at 37 ° C until the sample is completely dry. After that the particles were coated with gold and the images were taken with the magnifi cation of 20,000 and 40,000.
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DRUG ENTRAPMENT EFFICIENCY (DE)
To check the encapsulated drug in the prepared liposomal formulations, the maximum absorption of fl uconazole in the UV, 255 nm was obtained. Then, the calibration curve was drawn, and a specifi c amount of formulation is placed above the amicon fi lter and centrifuged for 5 minutes at 4 ° C and 4000 × g. A certain amount of free drug passes on the underside of Falcon removed by pipette and unloaded fl uconazole absorption was measured by spectrophotometer at a wavelength of 255 nm, and the percent of fl uconazole loading was obtained by the following formula:
RESULTS AND DISCUSSION
Eighty-seven positive cultures of yeast isolated from cutaneous, mucosal and systemic fungal lesions of patients referring Razi hospital in Tehran, Sina Hospital in Tabriz city and another private lab in Tabriz were collected. Due to the fact that more than one type of yeast wereisolated from some patient samples, the total number of 91 yeast colonies were isolated and tested in the next steps. The relevant results and methods of identifying can be seen in Table 1 .
The particle size of liposomal nanoparticles: In the present study, our goal was to obtain an ideal formulation in terms of particle size and the fl uconazole encapsulation amount for the evaluation of the antifungal effects and its comparison with the normal form of the drug, which is reached. As can be seen, the particle size of liposome containing fl uconazole is 88.9± 12.1 nm (Figure 3 ). Zeta potential for the fl uconazole liposome formulation is -12.20± 1.88mv (Figure 4) .
The SEM results for the nanoliposomes containing fl uconazole, to study the structure and form of the nanoliposomes the scanning electron microscope was used. The results are presented in Figure 5 ,6. Figure 5 is captured with a lower magnifi cation and to show a uniform distribution of particle size and Figure 6 is captured with a higher magnifi cation to better show the structure and form of the nanoliposomes, which are spheral.
The amount of fl uconazole loaded in the liposomal formulation is obtained as 75.1% in accordance with the aforementioned method. Table 2 represents the susceptibility of the examined Candida species to the fl uconazole and nanoliposomal fl uconazole medicines.In the present study, the produced liposomal formulation for more loading of the fl uconazole drug as well as its antifungal effects on the fl uconazole susceptible and resistant Candida species isolated from patients in the current form of fl uconazole were created.Poly dispersity index or PDI of the prepared nanoparticles:
ANTIFUNGAL SUSCEPTIBILITY TESTING
The results of the measurements using malvernzetasizer indicated that the formulation had a narrow particle distribution domain and the samples prepared to apply this method had a proper PDI and particle distribution. About the examination of the results of poly dispersity index or PDI of the prepared nanoparticles,it can be said that the lower the PDI, the lower the distribution of particle sizes is and the system will be more homogeneous. Generally, if PDI is in the range of 0 to 0.5, the suspension is mono disperse, and if it is higher than 0.5, it is poly disperse.
In this study, the standard method of Broth Microdilution described in CLSI M27-A3-S4 is presented and the standard quality control of C. parapsilosis ATCC 22019 was used to evaluate the MIC of fl uconazole and fl uconazole nanolipososmal formulation (J.H. Rex et al., 2008) .
To perform this test, 96-well microplateswere used. In order to dilute the fl uconazole stock solution, we used the growth medium RPMI1640 (with glutamine, without bicarbonate and buffered to pH 7.0). To prepare this medium, we solved 10.43 grams of RPMI powder and 34.53 grams of MOPS buffer (N-MorpholinoPropanesulfoni Acid) in one liter of distilled water with gentle shaking on the fl ame. We used normal saline for dilution of the Nanoliposomes containing fl uconazole. In the case of the two drugs, after adding to each drug the yeast cell suspension which had been prepared according to CLSI M27-A3 protocol and contained 2.5×10 3 to 0.5 × 10 3 cfu/ml of yeast, we obtained the highest and lowest fi nal concentrations as 64μg / ml and 0.063μlg /ml respectively. The well No. 12 was used as positive control. Each of the isolates was examined as dual series.
After 48 hours of incubation, to determine the Minimum Inhibitory Concentration (MIC) of fl uconazole and nanoliposomal fl uconazole that the fungus growing inside were not observed in the microplates and 80% of its growth was blocked, examined and the results were read.To ensure of the non-antifungal activity of nanoliposomes particles, blank nanoparticles liposome were used in this test and no antifungal effect was observed. We have used SPSS version 18 and Student's T-test in order to analyze and compare the antifungal effects of the liposomal nanoparticles containing fl uconazole and the free fl uconazole.
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Zeta potential of the fl uconazole liposome formulation:
Zeta potential is an important factor in determining the stability of the colloidal system and is the best indicator to determine the status of superfi cial electrical dispersions. Usually, cholesterol is used to improve the stability of liposomes. Adding cholesterol increases the zeta potential of the colloidal system; as the zeta potential increases in the particles, the particles will be more stable, and on the other hand, adding cholesterol will increase the rigidity of bilayer phospholipid (Mcnaught and Wilkinson, 1997, Panyam and V. Labhasetwar, 2003) .
In liposomal formulations, in the lipid composition of which there is cholesterol in addition to the lecithin, zeta potential was negative. About the stability of stearic and electrostatic combined, a minimum of ±20 ZP is desirable (Tang et al., 2014) . In a research by El-Nesr et al. in 2010 on multilayer liposomes containing fl uconazole, formulations with negative, neutral and positive zeta BIOSCIENCE BIOTECHNOLOGY RESEARCH COMMUNICATIONS the stearylamine particles in liposome and the slightly negative charge of the fl uconazole in comparison with the liposome particles with negative and neutral charge, (Ola et al., 2010) .
The amount of drug loaded in the liposomal formulation of fl uconazole:
The amount of drug loaded in the liposomal formulation was 75.11%. In fact, a signifi cant amount of fl uconazole was encapsulated in the nanoliposomes, which is due to the hydrophilic nature of fl uconazole that are not willing to be present in the external phase and as a result, a signifi cant amount of fl uconazole is encapsulated during the formation of nanoparticles.
The SEM results of nanoliposomes containing fl uconazole:
In the scanning electron microscope images, the narrow range of particle distribution and the spherical shape of the formed particles was clearly observable. According to the results of SEM, the prepared particles were in the same particle size range that was obtained by nanozetasizer.
The comparison of the antifungal effects of fl uconazole and liposomal nanoparticles containing fl uconazole: Table 2 shows the results of in vitro susceptibility of 6 susceptible and resistant Candida isolates to the fl uconazole comparing to the fl uconazole containing nanoliposome. As can be seen in the table 2, the use of the liposomal form of fl uconazole signifi cantly decreased the MIC of C.albicans species (P <0.0001), C.parapsilosis (P <0.05), C.tropicalis (P = 0.0005), C.glabrata (P = 0.002) and C.guilliermondii (P <0.05), but no difference was observed in the amount of MIC of the two forms of drug in the case of C.krusei.
The MIC 50 amount for C.glabrata was obtained as 8μg/ml, which had the highest amount of MIC relative to the nanoliposomes containing fl uconazole among the isolated Candida species of patients. The resistant strain potential were evaluated. This examination indicated that the nanoliposomes having positive, neutral and negative electric charge had the highest drug loading amount, respectively, and this can be possibly related to the electrostatic force between the positive charge of to the fl uconazole of C.glabrata which has MIC equal to 64 μg/ml, had 4 times decrease in the MIC and placed in the susceptible species after exposing to the fl uconazole liposomal form. The amount of MIC 50 for the fl uconazole susceptible strains of C.albicans, C.parapsilosis, C.tropicalis, and C.guilliermondii against to the fl uconazole liposomal form, were 1μg/ml, 1μg/ml, 1.5μg/ml and 2μg/ml, respectively. The amount of MIC 50 for the resistant strains of C.albicans, C.parapsilosis, C.krusei were 3μg/ml, 4μg/ml and 64 μg/ml, respectively.
There is a high possibility that the reason for the low amount of MIC in the fl uconazole resistant Candida strains relative to the nanoliposomal fl uconazole is related to the identifi ed resistance mechanisms of pathogenic fungi to drugs; the mechanisms that make fungi survive in the vicinity of a series of toxic substrates as well as antifungal drugs ( Mishra et al., 2007 , Morschhäuser, 2010 . Various molecular mechanisms have been identifi ed in the development of strains resistant to antifungal drugs (Franz et al., 1998) , that these mechanisms include reducing the transmission and diffusion of the drug into the cell, changes in the enzymes of the pathway of ergosterol Biosynthesis, changes in the target enzyme (point mutations, expression increase *Percent resistance using interpretive breakpoint criteria of the CLSI(M27-A3s4); Fluconazole resistance C. albicans, C.parapsilosis ≥ 8 μg/ml and C.glabrata≥ 64 μg/ml MIC(minimum inhibitory concentration), GM (Geometricmean)
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and gene change) and the increase of drug release to the outside by membrane diffusion pumps, activation of the enzymes that break down drugs outside the cell wall (Favre et al., 1999 , Hitchcock et al., 1990 , Li et al., 2004 , Löffl er et al., 1997 , Sanglard and Odds, 2002 , White et al., 1998 . From the mentioned cases, the most important reason for the resistance of Candida to the azole drugs is related to the expression of the high amount of transporter membrane proteins that lead to the pumping of azoles to the outside of the cell. The result is the reduction of drug concentration in cell and in this case, the drug concentration inside the cell is under the necessary level needed for creating the inhibitory effect on Erg11p (Caira et al., 2004) . Two main types of drug release pumps from the fungus cells causes their resistance to drugs: ABS and MFS (Lamping et al., 2010) . Cdr1 and Cdr2 are among the important transporters of the drug to the outside of the cell in C.albicans, C.glabrata and C.parapsilosis and the increase in their expression leads to the release of drug from the cell, which fi nally leads to the resistance of mentioned species to the fl uconazole (White et al., 2002 , Bennett et al., 2004 and Souza et al., 2015 .
In the examination conducted by us, the lipid nanoparticles are fused quickly with the cell membrane of yeast due to the hydrophobic outer surface, and as they are small in terms of size, they are capable of penetrating to the yeast cell and causes the drug protection against enzymes and effl ux pumps. Also, the lipid drug delivery systems due to the use biodegradable lipids are low toxic, have the ability to get lyophilized (Garud et al., 2012) and are capable of controlled release of the drugs, (Bose et al., 2013) .
In a recent study conducted by Moazeni et al. in 2016, using lipid nanoparticles against fl uconazole susceptible and resistant species in vitro, the results indicated the satisfying effect of lipid nanoparticles containing fl uconazole on the resistant strains of C.albicans, C.parapsilosis and C.glabrata (M. Moazeni et al., 2016) .
Similarly, Gupta et al. had observed that the use of drug delivery system can lead to the increase of fl uconazole penetration from the skin surface (Gupta et al., 2013) . As the fl uconazole prevents the synthesis of ergosterol by affecting the -demethylase14 enzyme, in the investigations of Venkateswarlu et al. it was determined that the -demethylase14 existing in the C.krusei differs the -demethylase14 of C.albicans (Venkateswarlu et al., 1997 , Venkateswarlu et al., 1996 .
Studies by Orozco et al. indicated that the intracellular accumulation of fl uconazole of C.krusei and C.albicans are similar (Orozco et al., 1998 ). This in turn could explain the reason why C.krusei was resistant to the fl uconazole exposure as well as the form of fl uconazole nanoparticles.
CONCLUSION
In the current study, the function of a new drug delivery system was evaluated on the fl uconazole resistant and susceptible Candida strains isolated from the patients. Although different mechanisms of resistance to fl uconazole are expressed, it seems that the resistance is due to the pumps releasing drug from the cell and it is one of the main reasons for these resistances. Therefore, it is likely that we can use the new system for drug delivery to prevent drug release from the cell. In addition, this is the fi rst research using fl uconazole lipid nanoparticles against C.krusei. 
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